| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Pfizer Global Research and Development, Groton Laboratories (H.Z.K., H.A.S., D.D.T.), Groton, Connecticut 06340; Pfizer Global Research and Development, Ann Arbor Laboratories (G.L.F.), Ann Arbor, Michigan 48105; and Skeletech, Inc. (V.S.), Bothell, Washington 98021
Address all correspondence and requests for reprints to: Dr. H. Z. Ke, Osteoporosis Research, Mail Stop 8118W-216, Pfizer Global Research and Development, Groton Laboratories, Groton, Connecticut 06340. E-mail: huazhu_ke{at}groton.pfizer.com.
The purpose of this study was to determine the long-term effects of lasofoxifene, a new selective estrogen receptor modulator, on bone mass, bone strength, and reproductive tissues in ovariectomized (OVX) rats. Sprague Dawley female rats at 3.5 months of age were OVX and treated orally with lasofoxifene (60, 150, or 300 µg/kg·d) for 52 wk. The urinary deoxypyridinoline/creatinine ratio was significantly lower in all lasofoxifene-treated OVX rats compared with OVX controls at wk 26. Peripheral quantitative computerized tomography analysis of proximal tibial metaphysis showed that the significant loss in trabecular content and density induced by OVX was significantly prevented by lasofoxifene treatment. Proximal tibial and lumber vertebral trabecular bone histomorphometric analysis showed that all doses of lasofoxifene significantly reduced OVX-induced bone loss by decreasing bone resorption and bone turnover. The ultimate strength, energy, and toughness of the fourth lumbar vertebral body in OVX rats treated with all doses of lasofoxifene were significantly higher compared with those in OVX controls, and did not differ significantly from those in sham controls. Uterine weight in OVX rats treated with lasofoxifene was slightly, but significantly, higher when compared with that in OVX controls, but was still much less than that in sham controls. No abnormal finding associated with lasofoxifene was observed with uterine histology examination. In summary, long-term treatment with lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in OVX rats. These data suggest that lasofoxifene is an effective antiosteoporosis agent, and its efficacy and safety can be maintained over an extended period of time.
This article has been cited by other articles:
 |
|
 |
|
  Y. Kharode, P. V. N. Bodine, C. P. Miller, C. R. Lyttle, and B. S. Komm The Pairing of a Selective Estrogen Receptor Modulator, Bazedoxifene, with Conjugated Estrogens as a New Paradigm for the Treatment of Menopausal Symptoms and Osteoporosis Prevention Endocrinology, December 1, 2008; 149(12): 6084 - 6091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Prakash, K. A. Johnson, and M. J. Gardner Disposition of Lasofoxifene, a Next-Generation Selective Estrogen Receptor Modulator, in Healthy Male Subjects Drug Metab. Dispos., July 1, 2008; 36(7): 1218 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Fountaine, Y. Nishizawa, G. Wei, L. Dogolo, A. Calcagni, and M. J. Gardner Clinical pharmacology of lasofoxifene in Japanese and white postmenopausal women. J. Clin. Pharmacol., June 1, 2006; 46(6): 693 - 699. [Full Text] [PDF]
|
|
|
|
|
|
C. Bramson, D. Ouellet, D. Roman, E. Randinitis, and M. J. Gardner A Single-Dose Pharmacokinetic Study of Lasofoxifene in Healthy Volunteers and Subjects With Mild and Moderate Hepatic Impairment J. Clin. Pharmacol., January 1, 2006; 46(1): 29 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A Moller, J. M Fisher, A. E Taylor, S. Kolluri, M. J Gardner, R S. Obach, and R. L Walsky Effects of Steady-State Lasofoxifene on CYP2D6- and CYP2E1-Mediated Metabolism Ann. Pharmacother., January 1, 2006; 40(1): 32 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Roman, C. Bramson, D. Ouellet, E. Randinitis, and M. Gardner Effect of Lasofoxifene on the Pharmacokinetics of Digoxin in Healthy Postmenopausal Women J. Clin. Pharmacol., December 1, 2005; 45(12): 1407 - 1412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.M. Helvering, M.D. Adrian, A.G. Geiser, S.T. Estrem, T. Wei, S. Huang, P. Chen, E.R. Dow, J. N. Calley, J.A. Dodge, et al. Differential Effects of Estrogen and Raloxifene on Messenger RNA and Matrix Metalloproteinase 2 Activity in the Rat Uterus Biol Reprod, April 1, 2005; 72(4): 830 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Sporn Arzoxifene: A Promising New Selective Estrogen Receptor Modulator for Clinical Chemoprevention of Breast Cancer: Commentary re C. J. Fabian et al., Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator. Clin Cancer Res 2004;10:5403-17. Clin. Cancer Res., August 15, 2004; 10(16): 5313 - 5315. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Madamanchi, X. Liu, and M. S. Runge A New Slice of Pie?: Estrogen Regulation of Plasminogen Activator Inhibitor-1 Circ. Res., August 6, 2004; 95(3): 228 - 229. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Turgeon, D. P. McDonnell, K. A. Martin, and P. M. Wise Hormone Therapy: Physiological Complexity Belies Therapeutic Simplicity Science, May 28, 2004; 304(5675): 1269 - 1273. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
